Greenland Mines Ltd (GRML) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US49876K1034

Price
5.14 USD
Market cap
4.98 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

Greenland Mines Ltd financials

Fiscal year2025
Operating income-7.15 m USD
EBIT-8.24 m USD
Net income-10.55 m USD
Diluted EPS – continuing operations-0.22 USD

Full history since 2021, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Greenland Mines Ltd

Greenland Mines Ltd engages in the cell and gene therapy, and natural resources businesses. The company primarily explores palladium, gold, and platinum deposits. It focuses on the exploration and development of Skaergaard project located in Southeast Greenland. The company is also involved in the development of KLTO-202, a gene therapy for the treatment and prevention of amyotrophic lateral sclerosis; and KLTO-101 for the treatment or prevention of Alzheimer's disease, as well as therapies to treat Parkinson's and other age-related disorders. The company was formerly known as Klotho Neurosciences, Inc. and changed its name to Greenland Mines Ltd in March 2026. Greenland Mines Ltd is based in Charlotte, North Carolina.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.